• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Beleave Begins Cannabinoid Clinical Research Program

April 26, 2017


TORONTO, ON--(Marketwired - April 26, 2017) - Beleave Inc. ("Beleave") (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it will begin a clinical research program with Dr. Mohit Bhandari, to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorders. In North America, Europe, and Australia, chronic non-cancer pain is a large contributor to morbidity, affecting as much as 30% of the population. Musculoskeletal disorders can be triggering events that lead to the development of chronic pain in up to 40% of chronic pain cases. Options for pain management in musculoskeletal disorders, both surgical and non-surgical, remain limited.


Dr. Bhandari is a Professor and a Canada Research Chair at McMaster University, a University Scholar, and the Associate Chair of Research for Surgery. He is a world-leading researcher specializing in large international clinical trials in orthopaedic surgery, and is among the most cited and well published surgical researchers in the world. His research team has expertise in the full spectrum of health research methods including systematic reviews, meta-analyses, epidemiological studies, economic analyses and clinical trials. Dr. Bhandari has won numerous awards for contributions to research and evidence-based orthopaedics including the Order of Ontario, and the Kappa Delta award.


"Chronic pain associated with musculoskeletal disorders is common and devastating," commented Beleave CEO, Roger Ferreira. "We are extremely happy to be partnering with Dr. Bhandari to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorder."


About Beleave


Beleave Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). Beleave's wholly-owned subsidiary First Access Medical Inc. ("FAM") has applied for a license to cultivate and sell medical cannabis pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and completed its pre-licensing inspection. Beleave's purpose-built facility is located near Hamilton, Ontario.


Forward-Looking Statements


This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.


Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.